Huttig Building Products, Inc.·Consumer Cyclical
Helix BioPharma Corp. (TSE: HBP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of C$1.88 and traded as high as C$1.99. Helix BioPharma shares last traded at C$1.99, with a volume of 1,411 shares trading hands. Helix BioPharma Stock Down
Toronto, Ontario – TheNewswire - 16 March, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and six-month periods ended January 31, 2026 (the “Financial Statements” ), the management's discussion and analysis ( “MD&A” ), and the certifications of the Chief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the Financial Statements (collectively, the “Interim Filings” ). All values are in Canadian dollars unless stated otherwise. “While our current financial position reflects a challenging capital markets environment for small-cap biotech companies, our focus remains firmly on securing the financing necessary to advance Helix into its next phase,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “The Management and Board are actively pursuing financing opportunities aimed at securing approximately twelve months of operating runway, which will allow the Company to pursue its near-term objectives, including listing on a U.S. securities exchange. While there is still work to be done, we have reason to be cautiously optimistic as we intensify these efforts and expect to communicate further on our roadmap to achieve this goal soon.”